Plain-English translation of NCT06479239 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new immunotherapy called EGFRBi Armed Fresh PBMC for people with advanced pancreatic cancer that cannot be removed by surgery. The treatment uses your own white blood cells, which are collected from your body, coated with a special protein in the laboratory to help them recognize cancer cells, and then given back to you as infusions. The goal is to help your immune system find and destroy cancer cells more effectively.
Pancreatic cancer is very difficult to treat, and current standard treatments don't work well enough for everyone. This trial exists to test whether training your own immune cells to recognize and attack pancreatic cancer could offer a new option for people whose cancer has not responded adequately to previous chemotherapy.
You likely qualify if…
You likely don't qualify if…
You will have a procedure called leukapheresis to collect your white blood cells—this is similar to donating blood and takes a few hours. Your cells will then be taken to a lab where they are coated with a special protein designed to help them fight cancer. About 3–4 days later, you will start receiving infusions of these treated cells every 2 weeks. After about 8–9 weeks, you will have another leukapheresis procedure, followed by 8 more infusions every 2 weeks. Throughout the trial, you will have regular blood tests and imaging scans to check how your cancer is responding and how your immune system is reacting to the treatment.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States